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Type I IFN and TNFα: cytokines with pleiotropic 
functions
Th   e family of type I IFN consists of multiple subtypes of 
IFNα, a single IFNβ and some less characterized family 
members, such as IFNε, IFNκ and IFNω. Th  e  diﬀ  erence 
in biological function between the multiple subtypes of 
type I IFN is unclear, especially since the induced genes 
downstream of the diﬀ   erent types of IFN (the IFN 
response program) are highly similar between, for 
example, IFNα and IFNβ. In peripheral blood, plasma-
cytoid dendritic cells (pDC) are the main producers of 
type I IFN. All nucleated cells, however, can produce type 
I IFN upon activation by, for example, viral infections 
that trigger cytoplasmic nucleic acid sensors such as 
TLR-7 and MDA-5.
Binding of type I IFNs to their cognate receptor (a 
heterodimer of IFNAR1 and IFNAR2) leads to the 
phos  phorylation of signal transducers and activators of 
trans  cription (STATs) and transcription of IFN response 
genes. Th  is results in resistance to viral replication, en-
hanced MHC class I expression and diﬀ  erentiation  of 
monocytes, all of which contribute to clear infection. 
Besides an essential role in the host antiviral state, type I 
IFN has immuno  regulatory functions by aﬀ  ecting  cell 
proliferation and diﬀ   erentiation and by inducing anti-
inﬂ   ammatory res  ponses. Considering these important 
functions of type I IFN in normal homeostasis as well as 
host response, an aberrant function in type I IFN immunity 
may contribute to autoimmunity and chronic inﬂ  amma-
tion. Th   is is illus  trated by the observation that melanoma 
patients treated with IFNα2β developed clinical and sero-
logical signs of autoimmunity [1] and that patients with a 
trisomy of chromosome 9, which contains the type I IFN 
genes, develop high IFN levels and lupus-like disease [2].
TNFα is a pivotal pro-inﬂ  ammatory cytokine produced 
by macrophages, activated T cells, natural killer cells and 
mast cells. Also non-immune, stromal cells are able to 
produce signiﬁ  cant amounts of TNFα. TNFα is produced 
as a 26 kDa transmembrane protein, which can be 
cleaved by TNFα converting enzyme to form the 17 kDa 
soluble form. Upon binding to TNFR1 (which is consti-
tutively expressed on most cell types) or TNFR2 (which is 
expressed on immune cells, endothelial cells and ﬁ  bro-
blasts), TNFα activates the mitogen-activated protein 
kinase and NF-κB signaling pathways [3] – which in turn 
can lead to an ampliﬁ   cation of the proinﬂ  ammatory 
response by increased production of chemokines and 
cytokines, including TNFα itself. Endothelial cells respond 
to TNFα by expressing adhesion molecules to facilitate 
traﬃ   cking of immune cells to the inﬂ  amed tissue. Macro-
phages and neutrophils are attracted to the site, increase 
their cyto  kine production, and enhance phagocytic 
capacities. Taken together, TNFα initiates and orches-
trates diﬀ   erent mechanisms that lead to an eﬀ  ective 
immune response in the case of infection.
Besides its role in host defense, however, TNFα is 
recognized to play a key role in many immune-mediated 
inﬂ   ammatory diseases (IMIDs), such as rheumatoid 
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© 2010 BioMed Central Ltdarthritis (RA), spondyloarthritis, psoriasis, and inﬂ  am-
ma  tory bowel disease [4]. Accordingly, anti-TNFα treat-
ment is very eﬀ  ective in these conditions. Interestingly, a 
recent animal study showed that the primary cell target 
of TNF in chronic inﬂ   ammatory joint and intestinal 
diseases is mesenchymal cells [5], a cell type that can 
produce large amounts of type I IFN.
Cross-regulation of TNFα and type I IFN: 
the hypothesis
Th  e relative contribution of TNFα and type I IFN to 
diﬀ   erent types of autoimmunity and inﬂ  ammatory 
disease is not well understood. An even more complex 
and intriguing picture emerged from the recently 
proposed hypothesis of an intimate interplay between 
both pleiotropic cytokines [6,7]. Th   is hypothesis proposes 
that, similarly to Th   1 and Th   2 cytokines in T-cell biology, 
both cytokines can be regarded as opposite vectors in 
many innate immune responses. If both vectors are in 
balance, the sum normally yields an equilibrium point 
allowing protective immunity. Disturbance of this 
balance beyond a certain threshold may contribute to 
pathological conditions such as autoimmunity and 
inﬂ  am  mation (Figure 1a). A shift towards the TNFα arm 
may create a permissive environment for TNF-mediated 
autoimmunity such as RA. In contrast, when the type I 
IFN arm prevails, IFN-driven autoimmunity such as 
systemic lupus erythematosus (SLE) may occur.
Th   is concept was ﬁ  rst formulated by Ivashkiv in 2003 
based on the clinical observation that a fraction of RA 
patients treated with anti-TNFα therapy develop 
antinuclear antibodies and even sometimes lupus-like 
syndromes that reverse with the cessation of the therapy 
[7]. Banchereau and colleagues further established this 
hypothesis after the observation that ﬁ  ve juvenile chronic 
arthritis patients treated with anti-TNFα therapy showed 
Figure 1. Cross-regulation between type I IFN and TNFα. (a) The original hypothesis proposes that both cytokines can be regarded as opposite 
vectors. Whereas the sum of both vectors normally yields an equilibrium point allowing protective immunity, disturbance of this balance beyond 
a certain threshold may contribute to a pathological state promoting autoimmunity, allergy, or infl  ammation. A shift towards the TNFα arm may 
create a permissive environment for TNF-mediated autoimmunity in rheumatoid arthritis (RA). In contrast, when the type I IFN arm prevails, IFN-
driven autoimmunity as observed in systemic lupus erythematosus (SLE) may occur. (b) An alternative hypothesis: in homeostatic conditions, type I 
IFN and TNFα are infl  uencing each other’s levels but this balance is lost in a pathological condition. (c) An alternative hypothesis: type I IFN plays an 
important role in the initiation of autoimmunity, while the role of TNFα increases during the secondary infl  ammatory phase.
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pheral blood mononuclear cell (PBMC) compartment 
compared with untreated control patients [6,8]. In 
addition, they showed that IFNα production by virally 
stimulated pDC is inhibited by TNFα through induction 
of maturation [8]. As this conceptual model may have 
important clinical implications for treatment with TNFα 
blockers or with type I IFN, the present review sum-
marizes and discusses the currently available clinical 
evidence for the proposed cross-regulation between 
TNFα and type I IFN at the cellular level as well as in vivo 
in experimental models and in IMID patients. A summary 
of all studies cited is presented in Tables 1 and 2.
Cross-regulation of TNFα and type I IFN at the 
cellular level
At the cellular level, the hypothesis of cross-regulation 
between TNFα and type I IFN is based on the observation 
that TNFα inhibits the generation of pDC as well as the 
secretion of type I IFN by immature pDC upon viral 
triggering [8]. Incubation of inﬂ  uenza-virus  activated 
pDC with TNFα inhibited the IFNα production by 40%, 
which was due to maturation of the pDC by TNFα rather 
than a direct inhibition or cross-regulation. In vitro 
culture of healthy PBMCs with the soluble TNFα recep-
tor etanercept resulted in a dose-dependent increase in 
the expression of IFNα and IFNα-inducible genes [9]. 
Th  ese studies speciﬁ  cally focused on IFNα and not on 
IFNβ, but similar genes are induced by IFNβ. In contrast 
with these ﬁ  ndings in PBMCs, studies on human ﬁ  bro-
blasts indicated that stimulation with TNFα induced an 
approximately 16-fold increase in the steady-state level of 
IFNβ mRNA [10]. Moreover, it has been shown more 
recently that TNFα induces a type I IFN response pro-
gram in macrophages through IFN regulatory factor-1 
activation, leading to an IFNβ-mediated autocrine loop 
[11]. Th   e TNFα canonical pathway and the IFNβ pathway 
may thereby synergize in the expression of downstream 
response genes. Taken together, these data suggest that 
the suppressive eﬀ  ect versus stimulating eﬀ  ect of TNFα 
on the synthesis of type I IFN is not universal but, rather, 
is cell-type dependent.
Th  e opposite question related to the presumed cross-
regulation is whether type I IFN suppresses TNFα 
production. Indeed, several studies have shown suppres-
sive eﬀ  ects of type I IFN. Stimulation of peripheral blood 
cells with IFNβ decreases the production of TNFα 
[12,13]. In addition, IFNβ augmented dexamethasone-
mediated suppression of TNFα in a human monocytic 
cell line [14]. A study on human macrophages indicated 
that IFNα can suppress TNFα production after immune 
complex, Fc receptor or Toll-like receptor stimulation by 
induction and activation of Axl, a receptor tyrosine 
kinase that induces the expression of a transcriptional 
repressor of the TNFα promoter [15]. Moreover, IFNβ 
can induce the expression of tristetraprolin, an RNA-
binding protein that destabilized the mRNA of pro-
inﬂ   am  matory cytokines including TNFα [16]. Accord-
ingly, IFN-induced tristetraprolin limits lipopolysac-
charide (LPS)-induced expression of several proinﬂ  am-
ma  tory cytokines, including TNFα, by macrophages.
Of interest, the inhibitory eﬀ  ect of IFNβ on TNFα 
production by human monocytes was shown to be 
stimulus dependent. IFNβ diminishes TNFα production 
in T-cell contact-activated monocytes, while IFNβ 
enhances TNFα production in LPS-activated monocytes 
[17]. Another study showed that direct stimulation of 
murine macro  phages with IFNβ does not suppress 
TNFα but, on the contrary, induces a fourfold 
upregulation of TNFα mRNA expression [18]. Whether 
the same holds true for IFNα awaits further 
investigation. Besides these direct eﬀ  ects,  low 
constitutive expression of type I IFN in many cell types 
contributes to boost the responsiveness towards other 
cytokines. Th  is phenomenon – called cross-priming – 
implicates that previous exposure to low doses of the 
pleiotropic type I IFN enhances subsequent response to 
proinﬂ  ammatory cytokines such as TNFα [19]. Taken 
together, these cellular studies yield conﬂ  icting results 
going from cross-priming to cross-regulation of TNFα 
production by type I IFN. Th   is may be partially due to 
diﬀ   erences in experimental settings mimicking 
homeostasis versus inﬂ  ammatory conditions.
Counterbalance of TNFα and type I IFN in 
experimental models of infl  ammation and 
autoimmunity
Th  e cellular studies indicated that the proposed cross-
regulation of type I IFN and TNFα may depend on both 
cell type and inﬂ  ammatory conditions, thereby empha-
sizing the need for additional information on this cross-
regulation in vivo in the context of tissue inﬂ  ammation 
and autoimmunity. Th   e NZB/W mouse, a model for SLE, 
bears a genetic defect in the TNFα gene that leads to 
reduced levels of TNFα [20]. Th  ese mice develop anti-
nuclear antibodies and nephritis. In accor  dance, 
treatment of the mice with TNFα resulted in attenuation 
of the disease.
An IFNα signature has been characterized in the 
splenic mononuclear cells of pre-autoimmune NZB/W 
mice that is not observed in BALB/c control mice [21]. 
Also, whereas IFNα serum levels are undetectable in both 
Balb/c control mice and NZB/W mice under homeostatic 
conditions, NZB/W mice but not Balb/c control mice 
produced IFNα after poly I:C stimulation [22]. On the 
other hand, IFNβ KO mice, which have an increased 
susceptibility to experi  mental autoimmune encephalo-
myelitis, display extensive microglia activation and TNFα 
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Page 3 of 10Table 1. Complex relation between TNFα and type I IFN in human studies
Cross- Cell  Activation  Experimental   
regulation type  state  model  Results  Reference
TNF   IFN   PBMCs  JIA  Anti-TNFα-treated vs. untreated   Patients treated with anti-TNFα showed higher  [8]
     patients  IFNα-regulated  genes
 PBMCs  Healthy  In vitro culture with etanercept  Dose-dependent increase in transcription of   [9]
        IFNα inducible genes
  Blood  RA  Infl  iximab-treated RA patients  Upregulation of type I IFN response genes only in   [52]
        patients with a poor clinical response
  Serum  SpA  Etanercept-treated SpA patients   Small increase in IFNα activity after 12 weeks  [53]
      (all good clinical response)  of treatment
  Plasma  SS  Etanercept-treated SS patients   Increase plasma in IFNα activity after 12 weeks  [9]
      (poor clinical response)  of treatment
  Plasma  Infl  ammatory   Infl  iximab-treated patients  Increase in serum type I IFN activity  [55]
    myopathy  (no clinical response)
TNF   IFN   Serum  SpA  Infl  iximab-treated SpA patients   Slightly decrease in IFNα activity after 2 weeks  [53]
      (all good clinical response)  that returns to baseline after 12 weeks
TNF   IFN   pDC  Infl  uenza virus  Incubation of virus-activated   TNFα inhibited IFNα, probably due to pDC maturation  [8]
     pDC  with  TNFα
TNF   IFN  Fibroblasts  Healthy  In vitro stimulation with TNFα  TNFα induced IFNβ mRNA levels  [10]
 Macrophages  Healthy  In vitro stimulation with TNFα  TNFα induced type I IFN response program through   [11]
        IFN regulatory factor-1, leading to an IFNβ-mediated 
       autocrine  loop
  Serum  Juvenile DM  TNF-308 promotor  Only in untreated patients: increased levels IFNα in   [43]
      polymorphism  carriers of minor allele, which is associated with 
       increased  TNFα  production
  PBMCs  RRMS  Concanavalin A-stimulated   More production of TNFα in concanavalin A-  [57]
      PBMCs obtained from IFNβ-  stimulated PBMCs after IFNβ treatment
      treated MS patients
  Monocytes  Healthy  Pre-incubation (30 min) with   IFNβ pretreatment enhanced LPS-induced TNFα  [17]
      IFNβ, subsequent stimulation   production by monocytes
     with  LPS
IFN   TNF  Macrophages Healthy  In vitro pretreatment with IFNα   IFNα suppressed FcγR-induced, TLR2-induced  [15]
      (100 U/ml) and subsequent   and TLR4-induced TNFα production through
      immune complexes, Fc receptor   induction of Axl, a repressor of TNFα promoter
     or  TLR  stimulation 
  PBMCs  RRMS  Anti-CD3-stimulated PBMCs   IFNβ therapy decreased the production of TNFα  [57]
      obtained from IFNβ-treated MS   by anti-CD3-stimulated PBMCs
     patients
  Synovial tissue  RA  Type I IFN treatment of RA  Decreased levels of TNFα in synovial tissue in some   [58]
     patients  patients
  PBMCs  Healthy  PHA and IFNβ-treated PBMCs  IFNβ decreased PHA-induced TNFα production   [12]
       by  PBMC
  Co-cultures of   Healthy  Co-cultures of T lymphocytes and  IFNβ inhibits the ability of stimulated T lymphocytes  [13]
  T lymphocytes     monocytes stimulated by PHA in  to induce cell contact-mediated TNFα production
  and monocytes    the presence of IFNβ   in monocytes
  THP-1  Cell line  Pre-incubation (24 hours) with   LPS-induced TNFα production by THP-1 cells  [14]
      IFNβ1b, subsequent stimulation   was suppressed by dexamethasone. This
      with LPS in the presence or   suppressive eff  ect was augmented by pre-incubation
      absence of dexamethasone  with IFNβ
  Monocytes   Healthy  Pre-incubation (30 min) with   Pretreatment with IFNβ decreased TNFα  [17]
      IFNβ, subsequent stimulation with   production by contact-activated monocytes
      plasma membranes of PHA + 
      PMA-stimulated HUT-78 cells
  PBMCs  Healthy  IFNβ administration and ex vivo   IFNβ induced a transient decrease of infl  ammatory  [56]
      mitogen stimulation of PBMCs  cytokines including TNFα
IFN   TNF   Blood and skin   SLE  Treatment with an anti-IFNα  Downmodulation of TNFα mRNA levels  [59]
  lesions    antibody in SLE patients
DM, dermatomyositis; HUT-78, human T-cell line; JIA, juvenile idiopathic arthritis; LPS, lipopolysaccharide; MS, multiple sclerosis; PBMC, peripheral blood mononuclear 
cell; pDC, plasmacytoid dendritic cells; PHA, phytohemagglutinin; PMA, phorbol myristate acetate; RA, rheumatoid arthritis; RRMS, relapsing-remitting multiple 
sclerosis; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; SS, Sjögren’s syndrome; THP-1, human monocytic cell line.
Cantaert et al. Arthritis Research & Therapy 2010, 12:219 
http://arthritis-research.com/content/12/5/219
Page 4 of 10production in the eﬀ   ector phase of the disease [23]. 
Macrophages isolated from these mice after experimental 
autoimmune encephalo  myelitis induction produced 
increased amounts of TNFα after stimulation with LPS 
and IFNγ, compared with wild-type controls [23]. In 
addition, these IFNβ KO mice are also more susceptible 
to collagen-induced arthritis and develop an exacerbated 
disease compared with control mice, with a greater 
production of TNFα [24]. Of interest, mice lacking the 
receptor for type I IFN (IFNAR1) or IFNβ are protected 
against TNFα-induced lethal shock [25] – showing that 
the absence of type I IFN signaling may not only impact 
TNFα production, but also the outcome of the TNFα-
induced inﬂ  ammation.
Th   ese observations also raise the reverse question: does 
increased type I IFN signaling downregulate TNFα pro-
duc  tion and/or TNF-induced inﬂ  ammation?  IFNβ 
treatment has a signiﬁ  cant therapeutic eﬀ  ect in collagen-
induced arthritis in mice and rhesus monkeys as well as 
in adjuvant arthritis in rats [26-28]. In these models, 
IFNβ was shown to have an inhibitory eﬀ   ect on the 
production of TNFα by LPS-stimulated macrophages 
[26]. Indirect upregulation of type I IFN also showed 
beneﬁ  cial eﬀ  ects in mouse models of arthritis [29,30]. In 
addition, mice treated with IFNβ had a 50% lowered 
expression of TNFα in the synovial tissue [28].
Taken together, these animal models demonstrate the 
presence and functionality of the cross-regulation 
between TNFα and type I IFN, but also indicate that this 
cross-regulation occurs mainly in a context-dependent 
manner during inﬂ  ammatory conditions (Table 2). Th  ese 
observations in turn raise the question of whether and to 
what extent the inﬂ  ammatory conditions seen in these 
experimental models are relevant for human IMIDs.
Cross-regulation of TNFα and type I IFN in immune-
mediated infl  ammatory diseases
Upregulation of type I IFN-response genes has now been 
observed in peripheral blood cells and/or target tissue in 
many diﬀ  erent IMIDs – for example, RA [31], SLE [32], 
systemic scleroderma [33], multiple sclerosis (MS) 
[34,35], psoriasis [36,37], Sjögren’s syndrome (SS) [38], 
dermatomyositis [39] and type 1 diabetes [40]. Th  ese 
ﬁ   ndings suggest that an activated type I IFN gene 
expression program may be a common denominator in 
chronic inﬂ   ammatory diseases in general. If cross-
regulation is present and eﬀ  ective, this activated type I 
IFN response program should lead to a repressed TNFα 
proﬁ   le. Most of these diseases, however, also have an 
elevated expression of TNFα both systemically and 
locally in the target tissues. For example, upregulation of 
both TNFα and type I IFN has been shown in lesional 
skin in psoriasis [37] as well as in synovial tissues of RA 
[41] and juvenile idiopathic arthritis patients [42]. Th  e 
question therefore arises of whether cross-regulation 
might be insuﬃ   cient in speciﬁ  c pathological conditions.
Table 2. Complex relation between TNF and type I IFN in murine studies
Cross- Cell  Activation  Experimental   
regulation type  state  model  Results  Reference
IFN   TNF   Embryonic fi  broblasts   p38 MAPK  In vitro stimulation with IFNβ and  In the presence of a p38 MAPK  [16]
  (MEF) and   stimulus  p38 MAPK stimulus simultaneously  stimulus, IFNβ induces – via STAT1 
  macrophages      activation – TTP, which destabilizes 
        mRNA of several proinfl  ammatory 
       genes  including  TNFα 
  Macrophages  IFNγ and LPS  Priming by IFNγ, stimulation by   IFNβ suppressed LPS/IFNγ induced  [26]
      LPS in the presence of IFNβ-EF   TNFα production 
     supernatant     
  Synovial tissue  CIA  Daily treatment of CIA using   FNβ treatment reduced TNFα   [28]
      recombinant IFNβ injection (7 days)  production in the synovial tissue
IFN   TNF  Macrophages  Healthy  In vitro stimulation with IFNβ  IFNβ mediated upregulation of TNF mRNA  [18]
IFN   TNF   Macrophages  LPS and IFNγ   EAE in IFNβ KO mice  Increased TNFα production compared   [23]
        with wild-type controls
  Spleen-derived   LPS and IFNγ  Cells isolated from IFNβ-defi  cient  Increased TNFα production compared  [24]
  macrophages    mice. Priming by IFNγ with   with control mice 
      subsequent stimulation with LPS   
  Synovial tissue  CIA  CIA in IFNβ-defi  cient mice  Increased TNFα production in synovia   [24]
        of arthritic IFNβ-defi  cient mice
IFN   TNF   Liver  TNFα-induced   IFNAR1 or IFNβ KO mice  Lack of type I IFN signaling protects  [25]
    lethal shock    against TNFα-induced infl  ammation 
TNF   IFN   Serum  Poly I:C  NZB/W mouse (defect in TNF)   NZB/W mice produce more poly I:C-  [22]
      injected with poly I:C  induced IFNα
CIA, collagen-induced arthritis; EAE, experimental autoimmune encephalomyelitis; EF, expressing fi  broblasts; LPS, lipopolysaccharide; MAPK, mitogen-activated 
protein kinase; MEF, muse embryonic fi  broblast; poly I:C, polyinosinic-polycytidylic acid; STAT, signal transducers and activators of transcription; TTP, tristetraprolin.
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studied in more detail in juvenile dermatomyositis. By 
measuring serum IFNα activity, higher serum IFNα levels 
were shown to be associated with the presence of the 
TNFα-308 promotor polymorphism [43]. Th  is poly-
morphism leads to increased production of TNFα in 50% 
of the carriers of the minor allele [44]. In early untreated 
patients, serum IFNα activity and TNFα are positively 
correlated. As the disease progresses, however, serum 
IFNα activity levels go down while TNFα levels remain 
stable [43]. Th  is observation indicates that type I IFN 
might be more important in the earliest phases of the 
auto  immune phase of disease, while TNF plays a more 
prominent role in the secondary eﬀ  ector phase of the 
disease (Figure 1b). Collectively, the relationship between 
both cytokines is inﬂ   uenced by timing and disease 
progression.
Th  e relationship between type I IFN and TNFα also 
appears to be complex in SLE. Patients with SLE display a 
strong type I IFN signature but also systemic over  expres-
sion of TNFα. Moreover, serum TNFα levels correlate 
with disease activity [45]. Recently, serum levels of both 
TNFα and IFNα were measured by ELISA in 171 SLE 
patients. Th  e patients showed elevated levels of both 
cytokines, and the correlation between both was highly 
signiﬁ  cant [46]. Another study, however, indicated that 
clustering of SLE patients according to serum IFNα 
activity and TNFα levels resulted in three groups: a group 
in which IFNα levels were much higher than TNFα levels, 
a group in which IFNα and TNFα levels were correlated, 
and a group in which TNFα levels were much higher than 
IFNα levels [47]. Th  e latter group had a weaker asso-
ciation with PTPN22 SNPs than the former two groups. 
Th  is study suggests that the relative balance between 
both cytokines may also be heterogeneous within one 
single disease.
Th   is heterogeneity was also conﬁ  rmed in MS, where a 
subgroup of patients displayed increased expression 
levels of type I IFN response genes in the peripheral 
blood [34]. Th   e extent of this type I IFN signature before 
treatment was inversely associated with the biological 
and clinical response to IFNβ treatment [35,48]. Elevated 
TNFα levels have been detected in the peripheral blood 
and brain lesions of MS patients, and correlated with 
disease activity [49], but it remains unknown whether 
there is a relationship with the type I IFN signature.
In RA, TNFα is overexpressed in the primary target 
tissue of the disease – the synovial membrane [50]. In 
addition, the expression of IFNβ as well as the number of 
IFNα-expressing and IFNβ-expressing pDC is signiﬁ  -
cantly elevated in RA synovial tissue compared with 
synovial tissues from patients with osteoarthritis or reac-
tive arthritis [41]. A similar picture emerges from 
peripheral blood, as about one-half of the RA patient 
population shows elevated expression levels of type I IFN 
response genes compared with healthy controls [31]. In 
the other half of the patients, the type I IFN response 
gene expression proﬁ   le is similar to that of healthy 
controls. Of interest, the peripheral blood IFN gene 
signature can already be observed in the preclinical phase 
of the disease [51]. Th  e clinical signiﬁ  cance  of  this 
elevated type I IFN expression proﬁ  le in blood is still 
unknown, as there is no diﬀ   erence in patient charac-
teristics or disease severity between patients with 
elevated or normal expression levels of type I IFN 
response genes. Th   us, in RA both cytokines appear to be 
elevated systemically as well as in the target tissue.
Together, these studies in diﬀ   erent IMIDs clearly 
indicate that there is no straightforward balance between 
the levels of type I IFN and TNFα, and that factors such 
as the speciﬁ   c type of IMID, the disease phase, and 
patient-speciﬁ   c factors may contribut  e to create a 
complex picture. One also has to consider that it is not 
completely clear how the absolute levels of these 
cytokines relate to their functional activity and role in 
disease pathogenesis.
Cross-regulation of TNFα and type I IFN during 
targeted treatment
Targeted therapies aimed at regulating cytokine activity 
provide an experimental approach to study cross-
regulation between TNFα and type I IFN in patients. In 
fact, the concept of TNFα/type I IFN cross-regulation 
proposed by Banchereau and colleagues was based on the 
observation that juvenile chronic arthritis patients 
treated with inﬂ  iximab (anti-TNFα monoclonal antibody) 
displayed increased transcription of IFNα-regulated 
genes compared with untreated patients. However, the 
inter-individual variability in the expression of IFNα, the 
relative small number of patients, and the cross-sectional 
design warranted further translational conﬁ  rmation  of 
these ﬁ  ndings in prospective studies.
Studying 33 RA patients during treatment with inﬂ  ixi-
mab, we observed no overall modulation of the expres-
sion of type I IFN response genes by TNFα blockade. 
Further analysis, however, revealed that inﬂ  iximab 
induced an upregulation of the type I IFN genes in a 
subset of patients with a poor clinical response to treat-
ment [52]. In contrast, the type I IFN response genes 
were not aﬀ  ected in patients with a good response to 
TNFα blockade. In spondyloarthritis, a disease that 
responds very well to TNFα blockade, inﬂ  iximab treat-
ment induced a small decrease of type I IFN serum 
activity after 2 weeks but the levels returned to baseline 
after 12 weeks of treatment. TNFα blockade with the 
soluble TNFα receptor etanercept led to a small increase 
in type I IFN serum activity after 12 weeks of treatment 
in a comparable patient population [53]. Similar results 
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myopathies. In SS patients, treatment with the soluble 
TNFα receptor construct etanercept, which is not 
clinically eﬀ   ective in SS [54], increased serum IFNα 
activity [9]. In patients with inﬂ  ammatory myopathies, 
inﬂ   iximab induced an increase in type I IFN serum 
activity without any clinical improvement and even 
disease exacerbation in some patients [55]. Collectively, 
these longitudinal studies indicate that the eﬀ  ect of TNFα 
blockade on type I IFN is not universal and may depend 
on the disease, the type of TNFα blocker, as well as the 
clinical response to treatment.
How are TNFα levels and/or activity aﬀ  ected by type I 
IFN treatment? In healthy volunteers, administration of 
IFNβ induced a transient decrease of the production of 
TNFα as well as other inﬂ  ammatory cytokines such as IL-
1β, IL-6 and lymphotoxin by PBMCs upon ex vivo stimu-
lation [56]. In MS, IFNβ treatment was also associated 
with decreased production of TNFα by anti-CD3-
stimulated PBMCs. In contrast, concanavalin A-stimulated 
PBMCs produced more TNFα after IFNβ treatment [57], 
indicating again that the proposed cross-regulation is not 
universal but is dependent on factors such as stimulus and 
cell type. In a proof-of-concept trial in RA patients [27], 
type I IFN treatment had an immuno  modulatory eﬀ  ect on 
synovial tissue inﬂ   am  ma  tion with decreased levels of 
synovial TNFα expression in some but not all patients [58]. 
Conversely, treatment with an anti-IFNα monoclonal 
antibody downmodulated TNFα m    RNA expression in 
peripheral blood and skin lesions in SLE patients [59]. 
Before treatment TNFα levels were increased compared 
with healthy controls, but the levels returned to normal 
1 day after anti-IFNα treatment. Th   ese data indicate that 
administration of type I IFNβ may lead to suppression of 
TNFα production in RA, whereas blocking IFNα does not 
directly entail elevation of TNFα levels. Consistent with 
preclinical studies, this experience with targeted inter-
ventions in patients highlights the dependence of the 
interaction between TNFα and type I IFN on the speciﬁ  c 
type I IFN subtype, the pathogenesis of the disease, and 
the intrinsic characteristics of the patient.
Clinical relevance of proposed cross-regulation 
between type I IFN and TNFα
Th  e cellular, experimental, and human data reviewed 
here indicate that cross-regulation between type I IFN 
and TNFα may occur in homeostatic conditions but is 
certainly not a universal principle in IMIDs. Th  e  presence 
or absence of the cross-regulation seems to depend on 
many factors, including the exact cell type, the type and 
level of activation, the speciﬁ  c IMID and, within a single 
IMID, the individual patient. Th  is complexity questions 
the potential clinical implications of the conceptual 
framework of type I IFN–TNFα cross-regulation. Th  ree 
relevant questions in this context are as follows: Can the 
type I IFN signature in IMID contribute to prediction of 
response to TNFα blockade? Can successful TNFα block-
ade induce type I IFN-driven adverse eﬀ  ects? And would 
IFN treatment be a viable option in TNF-driven IMIDs?
Since not all IMID patients respond well to anti-TNFα 
therapy, it is very relevant to identify biomarkers predict-
ing clinical eﬃ   cacy. Could the type I IFN signature be 
such a biomarker contributing to the prediction of 
response? Th  e expression of type I IFN response genes 
are upregulated after TNF blockade, especially in patients 
who have a poor clinical response to treatment [9,52]. In 
patients with a good response to treatment, the 
expression of type I IFN response genes seems unaﬀ  ected 
by TNFα blockade.
If the regulation of type I IFN is impeded by successful 
TNFα blockade, does this subsequently lead to type I 
IFN-driven adverse events? Type I IFN is known to play 
an important role in B-cell activation and plasma cell 
diﬀ   erentiation, and the levels are associated with the 
presence of autoantibodies in SLE [60]. Accordingly, it is 
conceivable that modulation of type I IFN by TNF 
blockade may have an impact on autoantibodies. In RA 
patients, however, TNF blockade had similar eﬀ  ects on 
the levels of circulating autoantibodies such as rheuma-
toid factor or anti-citrullinated protein antibodies in 
t y p e  I  I F N high patients and type I IFNlow patients [61]. 
Moreover, the induction of anti-nuclear antibodies by 
TNF blockade, a phenomenon that is frequently observed 
in both RA and spondyloarthritis [62], was not related to 
changes in the serum type I IFN activity [53]. From this 
we can conclude that there is no inﬂ  uence of the interplay 
between TNFα and type I IFN with respect to 
autoantibody production during TNF blockade.
Another intriguing side eﬀ  ect of TNF blockade is the 
induction of psoriasis-like disease in 3 to 5% of arthritis 
patients without pre-existing psoriasis, which was 
completely unexpected considering the excellent clinical 
response of psoriasis to TNF blockade [63]. Th  is side 
eﬀ  ect was hypothesized to be due to the proposed cross-
regulation between TNFα and type I IFN. Recent studies 
of human psoriatic tissue demonstrate that IFNα is 
present early in the disease process but is not detectable 
in the stable plaque, although downstream IFNα signal-
ing continues to be upregulated. [64]. Indeed, skin 
biopsies of four patients with anti-TNFα-induced psori-
asis displayed increased expression of myxovirus-
resistance protein A (a protein speciﬁ  cally induced by 
type I IFN) compared with biopsies from patients with 
psoriasis vulgaris [65]. It would be of interest to extend 
this cohort and analyze in more detail the type I IFN 
proﬁ  le to provide formal evidence for the hypothesis that 
TNFα blockade can induce or enhance type I IFN, and 
thereby psoriasis, in these patients.
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tial cross-regulation is whether type I IFN treat  ment 
could be a successful treatment strategy in TNF-driven 
IMIDs. In animal models for arthritis, a beneﬁ  cial eﬀ  ect 
of IFNβ treatment on both swelling and joint destruction 
has consistently been observed [26,28]. Similar results 
have been obtained in a collagen-induced arthritis model 
in rhesus monkeys [27]. A multicenter, randomized, 
double-blind, placebo-controlled phase II study of 
subcutaneous IFNβ1a in 209 patients with active RA, 
however, did not indicate a clinical or radiological eﬀ  ect 
[66]. Th  is discrepancy might relate to the mode of 
administration and the diﬀ  erence in IFNβ1a dosages used 
in man and mice. A successful example of IFNβ treatment 
is observed in MS, a disease in which TNFα has been 
shown to play an important role [49]. Further 
investigation of type I IFN therapy using innovative 
approaches is thus warranted in RA and other TNF-
driven IMIDs.
Conclusion
Th  e present review summarizes the currently available 
clinical evidence for the proposed cross-regulation 
between TNFα and type I IFN at the cellular level as well 
as in vivo in experimental models and in patients with 
IMIDs (Tables 1 and 2). Since both cytokines have pleio-
tropic eﬀ  ects that depend on the timing, dosage and cell 
type, the in vitro studies yielded conﬂ  icting results and 
indicated that the proposed cross-regulation is not as 
clear cut as anticipated. Moreover, the molecular mecha-
nism of cross-regulation between both cytokines is 
completely unclear and might be an indirect result 
through the induction of other factors. Most experi-
mental  in vivo models support the concept of cross-
regulation between both cytokines but again some 
studies yielded opposite results, conﬁ  rming the fact that 
the cross-regulation may be context dependent.
Th   e studies in patients with diﬀ  erent IMIDs show there 
is not necessarily a direct balance between the levels of 
type I IFN and TNFα, and that factors such as the type of 
IMID, the disease phase, and patient heterogeneity may 
contribute to create a complex picture. It is also possible 
in patients with IMIDs that both cytokines are elevated 
and are still inﬂ  uencing each other’s levels from rising 
even further.
An additional layer of complexity is added by the 
subtle diﬀ  erences in function of the diﬀ  erent subtypes 
of type I IFN and the diﬃ   culty to directly measure these 
individual isoforms. Th  e usage of type I IFN-induced 
genes is valuable, but this signature is not always a 
synonym for the presence of type I IFN speciﬁ  cally. 
Moreover, how the levels of these cytokines relate to 
their functional activity and role in disease pathogenesis 
is still to be investigated.
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